Evaluation of Neurodevelopmental Trajectories in Children According to the Glycemic Profile Associated With Different Early Treatment Modalities in Children With Type 1 Diabetes (T1DM)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-20

Study Completion Date

2028-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

More than half of all new cases of type 1 diabetes (T1D) are diagnosed in the first decade of life. It has been reported that early onset T1D may be associated with deterioration in cognitive performance. It mainly affects working memory or the ability to perform complex tasks involving planning (executive functions) or decision-making. Brain magnetic resonance imaging (MRI) has reported alteration brain growth alteration related to impaired cognitive performance. Exposure to hypoglycemia, hyperglycemia and glycemic variability are thought to be responsible for these structural changes, especially in younger patients. Those changes can be detected early after diagnosis. Automatized insulin delivery systems (AIDS) can dramatically improve glycemic profile in children with T1D by reducing the occurrence of hypo and hyperglycemia. However, in France, market authorization are limited to children with unbalanced T1D who have failed to respond to other therapies and to the reinforcement of diabetes education. It therefore does not concern newly diagnosed patients. 60% of patients under 10 diagnosed with T1DM for less than 3 years are not treated in France by these systems. The aim of this study is therefore to determine whether early treatment of patients with AIDS would have a positive impact on cerebral growth and and on cognitive function in pediatric patients with T1DM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neurocognitive Performance During Hyperglycemia , and Brain Tissue Integrity in Youth With Type 1 Diabetes and in Healthy

NCT02923323

Diabetes Mellitus, Type 1

UNKNOWN NA

Glycemic Control, Brain Structure and Cognition in Youth With Type 1 Diabetes (T1DM)

NCT00879203

Type 1 Diabetes Mellitis Cognition

COMPLETED

Pediatric Type 1 Diabetes and Neurocognitive Complications Cohort Study

NCT04135365

Type 1 Diabetes

COMPLETED

Neuropsychological and Neuroanatomical Studies of Young Children With and Without Type 1 Diabetes Mellitus

NCT00449891

Type 1 Diabetes Mellitus

COMPLETED

Brain Health and Development With T1DM

NCT03335878

T1DM Brain Development

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the study was to evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (use of a AIDS or Insulin pump combined with a continuous glucose monitoring sensor with the option of activating predictive shut-off before hypoglycemia (SAP-AAH)) and compared with an age-matched control subject.

Prospective case-control cohort study (T1DM or not) and exposed/non-exposed (CL or not), multicenter with 2 visits at 6 and 24 months of T1DM and 2 parallel visits for the control group.

The AIDS system used is a "mylife CamAPS application", marketed by CamDiab Ltd. class III, (YpsoPump, marketed by Ypsomed, Dexcom blood glucose sensor, used in their respective indications).

The experimental group will consist of patients treated with AIDS. The standard treatment (comparative) group will consist of patients with T1D treated with the gold standard treatment for this age group (SAP-AAH = insulin pump combined with a continuous glucose monitoring sensor with the option of activating predictive shut-off before hypoglycemia). In order to have a reference image, a second control group consisting of children aged 5 to 7 The expected benefits are early access to an automated insulin delivery system for study participants, as well as evidence of the neurocognitive benefit of early use of AIDs leading to changes in care practices.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AIDS group

patients with T1DM with automatized insulin delivery systems (AIDS)

Group Type EXPERIMENTAL

AIDS

Intervention Type DEVICE

mylife CamAPS application, marketed by CamDiab Ltd, in conjunction with YpsoPump, marketed by Ypsomed, Dexcom blood glucose sensor, Orbit Infusion sets and Orbit Infusion sets and Orbit inserter (used in their indications)

Brain MRI

Intervention Type OTHER

To evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (AIDS use or not) and compared with an age-matched control subject

TS group

patients with T1D treated with insulin pumps + blood glucose sensors with the option of activating predictive hypoglycemia shutdown (SAP-AAH)

Group Type OTHER

Brain MRI

Intervention Type OTHER

To evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (AIDS use or not) and compared with an age-matched control subject

Control group

age-matched control subjects without T1DM

Group Type OTHER

Brain MRI

Intervention Type OTHER

To evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (AIDS use or not) and compared with an age-matched control subject

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AIDS

mylife CamAPS application, marketed by CamDiab Ltd, in conjunction with YpsoPump, marketed by Ypsomed, Dexcom blood glucose sensor, Orbit Infusion sets and Orbit Infusion sets and Orbit inserter (used in their indications)

Intervention Type DEVICE

Brain MRI

To evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (AIDS use or not) and compared with an age-matched control subject

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Brain MRI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 5 to 7 years old
* Informed consent of parental guardians
* Parents able to speak, understand and read French (verified by investigator)
* Social security affiliation
* Only for subjects with T1DM:

* Insulin pump treatment and Dexcom sensor wear
* Type 1 diabetes diagnosed less than 6 months ago
* Insulin dose ≥ 0.5 IU/k/day
* Patients agree to use the DEXCOM sensor

Exclusion Criteria

* History of neurological disease
* History of child psychiatric disease
* Prematurity (birth before 37 SA)
* Wearing of internal metal parts contraindicating the performance of MRI
* Severe skin disease preventing the use of an insulin pump sensor or catheter
* Uncontrolled celiac disease
* Uncontrolled autoimmune thyroiditis
* Participation in another interventional research study or in the exclusion period thereof
* Refusal to participate by a minor after information adapted to his/her age and abilities

Minimum Eligible Age

5 Years

Maximum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes